Imexpharm (STC:IMP) Total Liabilities: ₫442,315 Mil (As of Mar. 2026)


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫42,050.00
GF Value ₫51,706.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Total Liabilities?

Imexpharm STC:IMP -1.98% 98 Total Liabilities is ₫442,315 Mil as of Mar. 2026. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Imexpharm's Total Liabilities for the quarter that ended in Mar. 2026 was ₫442,315 Mil.

Imexpharm's quarterly Total Liabilities declined from Sep. 2025 (₫768,402.50 Mil) to Dec. 2025 (₫476,112.31 Mil) and declined from Dec. 2025 (₫476,112.31 Mil) to Mar. 2026 (₫442,314.59 Mil).

Imexpharm's annual Total Liabilities increased from Dec. 2023 (₫308,036.21 Mil) to Dec. 2024 (₫321,657.50 Mil) and increased from Dec. 2024 (₫321,657.50 Mil) to Dec. 2025 (₫476,112.31 Mil).

Imexpharm Total Liabilities Historical Data

* Premium members only.

The historical data trend for Imexpharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imexpharm Total Liabilities Chart

Imexpharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 500,290.19 382,496.68 308,036.21 321,657.50 476,112.31

Imexpharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 666,800.66 902,921.79 768,402.50 476,112.31 442,314.59
STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imexpharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Imexpharm's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=372432.306+(100000+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+3680)
=476,112

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2782634.485-2306522.179
=476,112

Imexpharm's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=338634.591+(100000+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+3680)
=442,315

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2820855.359-2378540.768
=442,315

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₫442,315 Mil mean?
Imexpharm (STC:IMP) has a Total Liabilities of ₫442,315 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Imexpharm and its competitors.
Is Imexpharm's Total Liabilities too high?
Imexpharm's current Total Liabilities is ₫442,315 Mil. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Total Liabilities compare to ZTS?
Imexpharm's Total Liabilities of ₫442,315 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Imexpharm and its competitors. Imexpharm's current Total Liabilities is ₫442,315 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,050.00 — trading 18.7% below its estimated fair value. The current Total Liabilities is ₫442,315 Mil. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Total Liabilities is ₫442,315 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,050.00 is trading 18.7% below its estimated GF Value™ of ₫51,706.57. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Total Liabilities: ₫442,315 Mil
  • GF Value™: ₫51,706.57 vs. price of ₫42,050.00 (18.7% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,050.00
Price
₫51,706.57
GF Value